Evidence map›Paper›PMID 40121317›Full record

SynthesisEuropean journal of clinical nutrition2025

A systematic review of the impact of Elexacaftor/Tezacaftor/Ivacaftor on body composition in people with cystic fibrosis.

Laura Kinsey, Hannah Winterbottom, Lydia Hudson, Simon Lal, Andrew M Jones, Sorrel Burden

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in European journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura KinseyManchester Adult Cystic Fibrosis Centre, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, M23 9LT, United Kingdom. laura.kinsey@mft.nhs.uk.ORCID http://orcid.org/0009-0008-9789-574X
Hannah WinterbottomManchester Adult Cystic Fibrosis Centre, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, M23 9LT, United Kingdom.
Lydia HudsonManchester Adult Cystic Fibrosis Centre, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, M23 9LT, United Kingdom.
Simon LalIntestinal Failure Unit, Salford Royal Infirmary, Northern Care Alliance Foundation Trust, Manchester, United Kingdom.
Andrew M JonesManchester Adult Cystic Fibrosis Centre, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, M23 9LT, United Kingdom.
Sorrel BurdenIntestinal Failure Unit, Salford Royal Infirmary, Northern Care Alliance Foundation Trust, Manchester, United Kingdom.ORCID http://orcid.org/0000-0002-4967-647X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elexacaftor/Tezacaftor/Ivacaftor (ETI) has led to improved lung function, life expectancy, and body mass index for people with Cystic Fibrosis (CF). The aim of this systematic review was to evaluate the impact that ETI has had on body composition in people with CF. A systematic review was performed using MEDLINE, EMBASE, CINAHL, and the Cochrane Central Register of Controlled Trials. Quality assessment using the Joanna Briggs Institute critical appraisal tools were performed. Results were summarised narratively. Five observational cohort studies involving a total of 185 participants were reviewed. Three studies showed an increase in fat mass (7.0-8.6 kg, 13.2-14.3 kg, and 13.4-15.5 kg). Two studies reported an increase in fat-free mass (49.4-50.1 kg, 52.5-55 kg), while one reported a decrease (50.5-48.9 kg). Two studies found an increase in fat mass index (4.1-6.3 kgm/

Indexed as

AminophenolsBenzodioxolesBody CompositionCystic FibrosisIndolesPyrazolesPyridinesDrug CombinationsHumansPyrrolidinesQuinolonesAminophenolsBenzodioxolesDrug CombinationsIndolesivacaftorPyrazolesPyridinesPyrrolidinesQuinolones

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.